Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

References

• The Huntington’s Disease Collaborative Research GroupA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesCell19937269719838458085
   PubMed Web of Science ®Google Scholar
• NuciforaFCJrSasakiMPetersMFInterference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicityScience200129155122423242811264541
   PubMed Web of Science ®Google Scholar
• SubramaniamSSixtKMBarrowRSnyderSHRhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicityScience200932459321327133019498170
   PubMed Web of Science ®Google Scholar
• RibeiroFMPaquetMFerreiraLTMetabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington’s diseaseJ Neurosci201030131632420053912
   PubMed Web of Science ®Google Scholar
• AndrichJSaftCOstholtNMüllerTComplex movement behavior and progression of Huntington’s diseaseNeurosci Lett2007416327227417321683
   PubMed Web of Science ®Google Scholar
• FrankSMarshallFPlumbSFunctional decline due to chorea in Huntington’s diseaseNeurology200462Suppl 5A204
   Google Scholar
• VerhagenMLMorrisMJFarmerCHuntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadineNeurology200259569469912221159
   PubMed Web of Science ®Google Scholar
• BatesGHuntingtin aggregation and toxicity in Huntington’s diseaseLancet200336193691642164412747895
   PubMed Web of Science ®Google Scholar
• ArrasateMMitraSSchweitzerESSegalMRFinkbeinerSInclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature2004431701080581015483602
   PubMed Web of Science ®Google Scholar
• GlassMDragunowMFaullRLThe pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s diseaseNeuroscience200097350551910828533
   PubMed Web of Science ®Google Scholar
• AlbinRLReinerAAndersonKDPreferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s diseaseAnn Neurol19923144254301375014
   PubMed Web of Science ®Google Scholar
• ReinerAAlbinRLAndersonKDD’AmatoCJPenneyJBYoungABDifferential loss of striatal projection neurons in Huntington diseaseProc Natl Acad Sci U S A19888515573357372456581
   PubMed Web of Science ®Google Scholar
• MitchellIJCooperAJGriffithsMRThe selective vulnerability of striatopallidal neuronsProg Neurobiol199959669171910845758
   PubMed Web of Science ®Google Scholar
• AntoniniALeendersKLSpiegelRStriatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s diseaseBrain1996119Pt 6208520959010012
   PubMed Web of Science ®Google Scholar
• AugoodSJFaullRLEmsonPCDopamine D1 and D2 receptor gene expression in the striatum in Huntington’s diseaseAnn Neurol19974222152219266732
   PubMed Web of Science ®Google Scholar
• FeiginATangCMaYThalamic metabolism and symptom onset in preclinical Huntington’s diseaseBrain2007130Pt 112858286717893097
   PubMed Web of Science ®Google Scholar
• AndrewsTCWeeksRATurjanskiNHuntington’s disease progression. PET and clinical observationsBrain1999122Pt 122353236310581228
   PubMed Web of Science ®Google Scholar
• WeeksRAPicciniPHardingAEStriatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s diseaseAnn Neurol199640149548687191
   PubMed Web of Science ®Google Scholar
• ChaJHKosinskiCMKernerJAAltered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease geneProc Natl Acad Sci U S A19989511648064859600992
   PubMed Web of Science ®Google Scholar
• PerryTLHansenSKlosterMHuntington’s chorea. Deficiency of gamma-aminobutyric acid in brainN Engl J Med197328873373424345566
   PubMed Web of Science ®Google Scholar
• PaulsenJSFunctional imaging in Huntington’s diseaseExp Neurol2009216227227719171138
   PubMed Web of Science ®Google Scholar
• Gourfinkel-AnIParainKHartmannAChanges in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic miceJ Neurochem20038661369137812950446
   PubMed Web of Science ®Google Scholar
• NicniocaillBHaraldssonBHanssonOAltered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic miceEur J Neurosci200113120621011135020
   PubMed Web of Science ®Google Scholar
• LiSHLiXJHuntingtin-protein interactions and the pathogenesis of Huntington’s diseaseTrends Genet200420314615415036808
   PubMed Web of Science ®Google Scholar
• BenceNFSampatRMKopitoRRImpairment of the ubiquitin-proteasome system by protein aggregationScience200129255211552155511375494
   PubMed Web of Science ®Google Scholar
• RavikumarBDudenRRubinszteinDCAggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagyHum Mol Genet20021191107111711978769
   PubMed Web of Science ®Google Scholar
• ChaJHTranscriptional dysregulation in Huntington’s diseaseTrends Neurosci200023938739210941183
   PubMed Web of Science ®Google Scholar
• CepedaCHurstRSCalvertCRTransient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s diseaseJ Neurosci200323396196912574425
   PubMed Web of Science ®Google Scholar
• LudolphACHeFSpencerPSHammerstadJSabriM3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxinCan J Neurol Sci19911844924981782616
   PubMed Web of Science ®Google Scholar
• GunawardenaSGoldsteinLSPolyglutamine diseases and transport problems: deadly traffic jams on neuronal highwaysArch Neurol2005621465115642849
   PubMedGoogle Scholar
• BrowneSEBealMFThe energetics of Huntington’s diseaseNeurochem Res200429353154615038601
   PubMed Web of Science ®Google Scholar
• HarperPSThe epidemiology of Huntington’s diseaseHum Genet19928943653761535611
   PubMed Web of Science ®Google Scholar
• MorrisonPJJohnstonWPNevinNCThe epidemiology of Huntington’s disease in Northern IrelandJ Med Genet19953275245307562964
   PubMed Web of Science ®Google Scholar
• PeterlinBKobalJTeranNEpidemiology of Huntington’s disease in SloveniaActa Neurol Scand2009119637137518976322
   PubMed Web of Science ®Google Scholar
• AlonsoMEOchoaABollMCClinical and genetic characteristics of Mexican Huntington’s disease patientsMov Disord200924132012201519672992
   PubMed Web of Science ®Google Scholar
• SimpsonSAJohnstonAWThe prevalence and patterns of care of Huntington’s chorea in GrampianBr J Psychiatry19891557998042533515
   PubMed Web of Science ®Google Scholar
• PenneyJBJrYoungABShoulsonIHuntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individualsMov Disord19905293992139171
   PubMed Web of Science ®Google Scholar
• HarperPSThe epidemiology of Huntington’s diseaseBatesGHarperPJonesLHuntington’s disease3rd edOxfordMonographs on Medical Genetics2002
   Google Scholar
• RibaiPNguyenKHahn-BarmaVPsychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patientsArch Neurol200764681381917562929
   PubMedGoogle Scholar
• BiglanKMRossCALangbehnDRPREDICT-HD Investigators of the Huntington Study GroupMotor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD studyMov Disord200924121763177219562761
   PubMed Web of Science ®Google Scholar
• TabriziSJLangbehnDRLeavittBRTRACK-HD investigatorsBiological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline dataLancet Neurol20098979180119646924
   PubMed Web of Science ®Google Scholar
• Huntington Study Group PHAROS Investigators (Shoulson I, primary author)At risk for Huntington’s disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolledArch Neurol200663799199616831969
   PubMedGoogle Scholar
• Huntington Study GroupCooperative Huntington’s Observational Research Trial [ClinicalTrials.gov identifier NCT00313495]US National Institutes of Health Available from: http://www.clinicaltrials.govAccessed May 3, 2010
   Google Scholar
• SolomonACStoutJCJohnsonSAPredict-HD Investigators of the Huntington Study GroupVerbal episodic memory declines prior to diagnosis in Huntington’s diseaseNeuropsychologia20074581767177617303196
   PubMed Web of Science ®Google Scholar
• JohnsonSAStoutJCSolomonACPredict-HD Investigators of the Huntington Study GroupBeyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington’s diseaseBrain2007130Pt 71732174417584778
   PubMed Web of Science ®Google Scholar
• PaulsenJSLangbehnDRStoutJCPredict-HD Investigators and Coordinators of the Huntington Study GroupDetection of Huntington’s disease decades before diagnosis: the Predict-HD studyJ Neurol Neurosurg Psychiatry200879887488018096682
   PubMed Web of Science ®Google Scholar
• DuffKPaulsenJSBeglingerLJPredict-HD Investigators of the Huntington Study GroupPsychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD studyBiol Psychiatry200762121341134617481592
   PubMed Web of Science ®Google Scholar
• Huntington Study GroupUnified Huntington’s Disease Rating Scale: reliability and consistencyMov Disord19961121361428684382
   PubMed Web of Science ®Google Scholar
• The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working GroupACMG/ASHG statement. Laboratory guidelines for Huntington disease genetic testingAm J Hum Genet1998625124312479545416
   PubMed Web of Science ®Google Scholar
• AndrichJArningLWieczorekSKrausPHGoldRSaftCHuntington’s disease as caused by 34 CAG repeatsMov Disord200823687988118307262
   PubMed Web of Science ®Google Scholar
• KenneyCPowellSJankovicJAutopsy-proven Huntington’s disease with 29 trinucleotide repeatsMov Disord200722112713017115386
   PubMed Web of Science ®Google Scholar
• SnellRGMacMillanJCCheadleJPRelationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s diseaseNat Genet1993443933978401588
   PubMed Web of Science ®Google Scholar
• DiMLSquitieriFNapolitanoGCampanellaGTrofatterJAConneallyPMSuicide risk in Huntington’s diseaseJ Med Genet19933042932958487273
   PubMed Web of Science ®Google Scholar
• PollardJHurry Up and Wait: a cognitive care companion9/25/08 142 pagesLulu press
   Google Scholar
• AdamORJankovicJSymptomatic treatment of Huntington diseaseNeurotherapeutics20085218119718394562
   PubMed Web of Science ®Google Scholar
• PhillipsWShannonKMBarkerRAThe current clinical management of Huntington’s diseaseMov Disord200823111491150418581443
   PubMed Web of Science ®Google Scholar
• RozeESaudouFCabocheJPathophysiology of Huntington’s disease: from huntingtin functions to potential treatmentsCurr Opin Neurol200821449750318607213
   PubMed Web of Science ®Google Scholar
• ImarisioSCarmichaelJKorolchukVHuntington’s disease: from pathology and genetics to potential therapiesBiochem J200841219120918466116
   PubMed Web of Science ®Google Scholar
• WalkerFOHuntington’s diseaseLancet2007369955721822817240289
   PubMed Web of Science ®Google Scholar
• JankovicJTreatment of hyperkinetic movement disordersLancet Neurol20098984485619679276
   PubMed Web of Science ®Google Scholar
• BonelliRMWenningGKPharmacological management of Huntington’s disease: an evidence-based reviewCurr Pharm Des200612212701272016842168
   PubMed Web of Science ®Google Scholar
• MestreTFerreiraJCoelhoMMRosaMSampaioCTherapeutic interventions for symptomatic treatment in Huntington’s diseaseCochrane Database Sys Rev20093CD006456
   Web of Science ®Google Scholar
• NakamuraKAminoffMJHuntington’s disease: clinical characteristics, pathogenesis and therapiesDrugs Today (Barc)20074329711617353947
   PubMed Web of Science ®Google Scholar
• HandleyOJNajiJJDunnettSBRosserAEPharmaceutical, cellular and genetic therapies for Huntington’s diseaseClin Sci (Lond)20061101738816336206
   PubMed Web of Science ®Google Scholar
• BonelliRMHofmannPA review of the treatment options for Huntington’s diseaseExpert Opin Pharmacother20045476777615102562
   PubMed Web of Science ®Google Scholar
• GrimbergenYARoosRATherapeutic options for Huntington’s diseaseCurr Opin Investig Drugs2003415154
   Google Scholar
• FrankSAJankovicJAdvances in the pharmacological management of Huntington’s DiseaseDrugs201070556157120329804
   PubMed Web of Science ®Google Scholar
• PaleacuDTetrabenazine in the treatment of Huntington’s DiseaseNeuropsychiatr Dis Treat20073554555119381278
   PubMedGoogle Scholar
• BagchiSPDifferential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamineBiochem Pharmacol19833219285128566626259
   PubMed Web of Science ®Google Scholar
• PettiboneDJPfluegerABTotaroJATetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrineEur J Pharmacol198410234431436
   Web of Science ®Google Scholar
• MehvarRJamaliFConcentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the ratJ Pharm Sci19877664614653625491
   PubMed Web of Science ®Google Scholar
• ThibautFFaucheuxBAMarquezJRegional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson’s disease: a postmortem study using tritiated tetrabenazineBrain Res1995692122332438548292
   PubMed Web of Science ®Google Scholar
• KenneyCHunterCDavidsonAJankovicJShort-term effects of tetrabenazine on chorea associated with Huntington’s diseaseMov Disord2007221101317078062
   PubMed Web of Science ®Google Scholar
• SchermanDHenryJPReserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine bindingMol Pharmacol19842511131226708929
   PubMed Web of Science ®Google Scholar
• MehvarRJamaliFWatsonMWSkeltonDPharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studiesDrug Metab Dispos19871522502552882986
   PubMed Web of Science ®Google Scholar
• RobertsMSWatsonHMMcLeanSMillingenKSDetermination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatographyJ Chromatogr198122611751826459332
   PubMed Web of Science ®Google Scholar
• RobertsMSMcLeanSMillingenKSGallowayHMThe pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disordersEur J Clin Pharmacol19862967037083709613
   PubMed Web of Science ®Google Scholar
• Huntington Study GroupTetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trialNeurology200666336637216476934
   PubMed Web of Science ®Google Scholar
• JankovicJBeachJLong-term effects of tetrabenazine in hyperkinetic movement disordersNeurology19974823583629040721
   PubMed Web of Science ®Google Scholar
• KenneyCHunterCJankovicJLong-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disordersMov Disord200722219319717133512
   PubMed Web of Science ®Google Scholar
• FasanoACadedduFGuidubaldiAThe long-term effect of tetrabenazine in the management of Huntington diseaseClin Neuropharmacol200831631331819050408
   PubMed Web of Science ®Google Scholar
• FrankSTetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD InvestigatorsBMC Neurol200996220021666
   PubMed Web of Science ®Google Scholar
• FrankSOndoWFahnSA study of chorea after tetrabenazine withdrawal in patients with Huntington’s diseaseClin Neuropharmacol200831312713318520979
   PubMed Web of Science ®Google Scholar
• QuinnNMarsdenCDA double blind trial of sulpiride in Huntington’s disease and tardive dyskinesiaJ Neurol Neurosurg Psychiatry19844788448476236286
   PubMed Web of Science ®Google Scholar
• DerooverJBaroFBourguignonRPSmetsPTiapride versus placebo: a double-blind comparative study in the management of Huntington’s choreaCurr Med Res Opin1984953293386241563
   PubMed Web of Science ®Google Scholar
• LeonardDPKidsonMABrownJGShannonPJTaryanSA double blind trial of lithium carbonate and haloperidol in Huntington’s choreaAust N Z J Psychiatry197592115118125578
   PubMed Web of Science ®Google Scholar
• BarrANFischerJHKollerWCSpuntALSinghalASerum haloperidol concentration and choreiform movements in Huntington’s diseaseNeurology198838184882962009
   PubMed Web of Science ®Google Scholar
• BonelliRMMahnertFANiederwieserGOlanzapine for Huntington’s disease: an open label studyClin Neuropharmacol200225526326512410058
   PubMed Web of Science ®Google Scholar
• BonelliRMNiederwieserGTriblGGKöltringerPHigh-dose olanzapine in Huntington’s diseaseInt Clin Psychopharmacol2002172919311890191
   PubMed Web of Science ®Google Scholar
• PaleacuDAncaMGiladiNOlanzapine in Huntington’s diseaseActa Neurol Scand2002105644144412027832
   PubMed Web of Science ®Google Scholar
• SquitieriFCannellaMPiorcelliniABrusaLSimonelliMRuggieriSShort-term effects of olanzapine in Huntington diseaseNeuropsychiatry Neuropsychol Behav Neurol2001141697211234911
   PubMedGoogle Scholar
• DippleHCThe use of olanzapine for movement disorder in Huntington’s disease: a first case reportJ Neurol Neurosurg Psychiatry199967112312410454874
   PubMed Web of Science ®Google Scholar
• CankurtaranESOzalpESoygurHCakirAClinical experience with risperidone and memantine in the treatment of Huntington’s diseaseJ Natl Med Assoc20069881353135516916137
   PubMed Web of Science ®Google Scholar
• ErdemogluAKBoratavCRisperidone in chorea and psychosis of Huntington’s diseaseEur J Neurol20029218218311882064
   PubMed Web of Science ®Google Scholar
• MadhusoodananSBrennerRUse of risperidone in psychosis associated with Huntington’s diseaseAm J Geriatr Psychiatry1998643473499793585
   PubMed Web of Science ®Google Scholar
• ParsaMASzigethyEVociJMMeltzerHYRisperidone in treatment of choreoathetosis of Huntington’s diseaseJ Clin Psychopharmacol199717213413510950488
   PubMed Web of Science ®Google Scholar
• AlpayMKoroshetzWJQuetiapine in the treatment of behavioral disturbances in patients with Huntington’s diseasePsychosomatics2006471707216384811
   PubMed Web of Science ®Google Scholar
• SeitzDPMillsonRCQuetiapine in the management of psychosis secondary to Huntington’s disease: a case reportCan J Psychiatry200449641315283541
   PubMed Web of Science ®Google Scholar
• BonelliRMNiederwieserGQuetiapine in Huntington’s disease: a first case reportJ Neurol200224981114111512420714
   PubMed Web of Science ®Google Scholar
• van VugtJPSieslingSVergeerMvan der VeldeEARoosRAClozapine versus placebo in Huntington’s disease: a double blind randomised comparative studyJ Neurol Neurosurg Psychiatry199763135399221965
   PubMed Web of Science ®Google Scholar
• CiammolaASassoneJColciagoCAripiprazole in the treatment of Huntington’s disease: a case seriesNeuropsychiatr Dis Treat200951419557093
   PubMed Web of Science ®Google Scholar
• BrusaLOrlacchioAMoschellaVIaniCBernardiGMercuriNBTreatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazineMov Disord200924112612919170197
   PubMed Web of Science ®Google Scholar
• LinWCChouYHAripiprazole effects on psychosis and chorea in a patient with Huntington’s diseaseAm J Psychiatry200816591207120818765501
   PubMed Web of Science ®Google Scholar
• LucettiCGambacciniGBernardiniSAmantadine in Huntington’s disease: open-label video-blinded studyNeurol Sci200223Suppl 2S83S8412548355
   PubMed Web of Science ®Google Scholar
• StewartJTAdverse behavioral effects of amantadine therapy in Huntington’s diseaseSouth Med J19878010132413252958943
   PubMed Web of Science ®Google Scholar
• Huntington Study GroupDosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled studyNeurology200361111551155614663041
   PubMed Web of Science ®Google Scholar
• LandwehrmeyerGBDuboisBde YebenesJGRiluzole in Huntington’s disease: a 3-year, randomized controlled studyAnn Neurol200762326227217702031
   PubMed Web of Science ®Google Scholar
• PeirisJBBoralessaHLionelNDClonazepam in the treatment of choreiform activityMed J Aust197618225227131236
   PubMed Web of Science ®Google Scholar
• FrattolaLAlbizzatiMGAlemaniABassiSFerrareseCTrabucchiMAcute treatment of Huntington’s chorea with lisurideJ Neurol Sci19835922472536222164
   PubMed Web of Science ®Google Scholar
• VitaleCMarconiSDiMLShort-term continuous infusion of apomorphine hydrochloride for treatment of Huntington’s chorea: a double blind, randomized cross-over trialMov Disord200722162359236417894335
   PubMed Web of Science ®Google Scholar
• CorsiniGUOnaliPMasalaCCianchettiCMangoniAGessaGApomorphine hydrochloride-induced improvement in Huntington’s chorea: stimulation of dopamine receptorArch Neurol19783512730145840
   PubMedGoogle Scholar
• LowPAAllsopJLHalmagyiGMHuntington’s chorea: the rigid form (Westphal variant) treated with levodopaMed J Aust19741113933944275254
   PubMed Web of Science ®Google Scholar
• LowPAAllsopJLHuntington’s chorea – the rigid form (Westphal variant) treated with l-DOPA: a case reportProc Aust Assoc Neurol197310045464275960
   PubMedGoogle Scholar
• MagnetMKBonelliRMKapfhammerHPAmantadine in the akinetic-rigid variant of Huntington’s diseaseAnn Pharmacother2004387811941196
   Web of Science ®Google Scholar
• BonelliRMNiederwieserGDiezJGruberAKöltringerPPramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington’s diseaseClin Neuropharmacol2002251586011852299
   PubMed Web of Science ®Google Scholar
• http://www.xenazineusa.comAccessed 3 May 2010
   Google Scholar